Biorion

biorion: fighting fibrosis biorion is a pre-clinical stage dutch biopharmaceutical company developing targeted therapies and companion imaging diagnostics for personalized treatment of patients with fibrosis. the company is using its proprietary platform technology of pdgf-beta-receptor-binding cyclic peptides. pdgf-beta-receptors are selectively upregulated on myofibroblasts, the key pathogenic cells in fibrosis, and allow tissue specific targeting, likely in an early stage of the disease. biorion believes that fibrosis can be best treated by direct targeting myofibroblasts. several metabolic or inflammatory up-stream targets have shown limited or no beneficial effect on fibrosis. bot501, our radioactive 68ga-pet-labeled pdgf-beta-receptor-binding synthetic cyclic peptide is in development for non-invasive imaging of liver fibrosis in nash, renal fibrosis in diabetic nephropathy and cardial fibrosis. bot191 is a full synthetic therapeutic peptide, containing the interferon-gamma signa